Intellia Therapeutics price target lowered to $50 from $60 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $60 and keeps an Overweight rating on the shares. Most notable takeaways from Q4 update, in the firm’s view, are that longer follow-up in HAE study may show greater functional cure rate, and that ATTR-CM enrollment continues tracking ahead of expectation, indicating acceptance of gene editing modality.